SLC5A2 and acute kidney injury: Interestingly, a meta-analysis of 112 randomized clinical trials and 4 observational studies with 5 cohorts consisting of 180656 diabetic patients revealed that SGLT2 inhibitors decreased the odds of acute kidney injury (AKI) by 36% (odds ratio (OR) 0.64, 95% CI (0.53-0.78)) among those patients [5].